 Brianne Bettcher
Concepts (270)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alzheimer Disease | 25 | 2024 | 436 | 5.210 |
Why?
| | White Matter | 8 | 2023 | 102 | 3.070 |
Why?
| | Cognition Disorders | 13 | 2023 | 476 | 1.920 |
Why?
| | Aging | 18 | 2023 | 1621 | 1.820 |
Why?
| | Dementia | 9 | 2017 | 186 | 1.510 |
Why?
| | Cognition | 11 | 2023 | 981 | 1.510 |
Why?
| | Memory, Episodic | 4 | 2021 | 38 | 1.490 |
Why?
| | Activities of Daily Living | 8 | 2021 | 350 | 1.470 |
Why?
| | Executive Function | 10 | 2021 | 376 | 1.270 |
Why?
| | Cognitive Dysfunction | 11 | 2023 | 273 | 1.270 |
Why?
| | Psychomotor Performance | 7 | 2021 | 280 | 1.190 |
Why?
| | Aged, 80 and over | 34 | 2021 | 6363 | 1.150 |
Why?
| | Neuropsychological Tests | 25 | 2021 | 913 | 1.090 |
Why?
| | Signal Detection, Psychological | 3 | 2011 | 21 | 1.070 |
Why?
| | Aged | 50 | 2023 | 19120 | 0.990 |
Why?
| | Inflammation | 6 | 2023 | 2485 | 0.970 |
Why?
| | Gliosis | 2 | 2023 | 29 | 0.960 |
Why?
| | Encephalitis | 3 | 2014 | 127 | 0.870 |
Why?
| | Brain | 12 | 2023 | 2372 | 0.820 |
Why?
| | Memory Consolidation | 1 | 2021 | 11 | 0.770 |
Why?
| | Biofeedback, Psychology | 2 | 2011 | 25 | 0.760 |
Why?
| | Healthy Aging | 1 | 2021 | 17 | 0.740 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2021 | 79 | 0.730 |
Why?
| | Memory, Short-Term | 4 | 2019 | 223 | 0.720 |
Why?
| | Temporal Lobe | 4 | 2021 | 79 | 0.720 |
Why?
| | Diffusion Tensor Imaging | 5 | 2023 | 62 | 0.710 |
Why?
| | Immune System | 1 | 2021 | 173 | 0.700 |
Why?
| | Fornix, Brain | 1 | 2019 | 6 | 0.680 |
Why?
| | Neurogenesis | 1 | 2021 | 102 | 0.680 |
Why?
| | Atrophy | 7 | 2024 | 151 | 0.670 |
Why?
| | Cognitive Reserve | 1 | 2019 | 14 | 0.670 |
Why?
| | Astrocytes | 1 | 2021 | 162 | 0.660 |
Why?
| | Neurodegenerative Diseases | 2 | 2012 | 91 | 0.650 |
Why?
| | Memory | 7 | 2014 | 209 | 0.640 |
Why?
| | Anisotropy | 5 | 2021 | 61 | 0.590 |
Why?
| | Autoimmune Diseases of the Nervous System | 2 | 2014 | 21 | 0.580 |
Why?
| | Corpus Callosum | 2 | 2014 | 56 | 0.580 |
Why?
| | Memory Disorders | 2 | 2017 | 154 | 0.570 |
Why?
| | Middle Aged | 34 | 2021 | 26801 | 0.560 |
Why?
| | Surgical Procedures, Operative | 1 | 2019 | 206 | 0.560 |
Why?
| | Potassium Channels, Voltage-Gated | 3 | 2014 | 48 | 0.520 |
Why?
| | Humans | 65 | 2024 | 114925 | 0.520 |
Why?
| | Interleukin-6 | 3 | 2018 | 676 | 0.510 |
Why?
| | Male | 47 | 2021 | 55655 | 0.490 |
Why?
| | Cholesterol | 1 | 2017 | 368 | 0.490 |
Why?
| | Magnetic Resonance Imaging | 18 | 2024 | 3053 | 0.480 |
Why?
| | Female | 45 | 2023 | 59571 | 0.470 |
Why?
| | Language Disorders | 1 | 2014 | 32 | 0.470 |
Why?
| | Biomarkers | 8 | 2023 | 3418 | 0.470 |
Why?
| | Prefrontal Cortex | 1 | 2016 | 261 | 0.430 |
Why?
| | C-Reactive Protein | 2 | 2014 | 362 | 0.430 |
Why?
| | Brain Mapping | 1 | 2016 | 522 | 0.410 |
Why?
| | Frontotemporal Dementia | 3 | 2016 | 20 | 0.400 |
Why?
| | Cerebral Cortex | 3 | 2022 | 381 | 0.400 |
Why?
| | Environment | 2 | 2011 | 334 | 0.400 |
Why?
| | tau Proteins | 6 | 2023 | 68 | 0.390 |
Why?
| | Diffusion Magnetic Resonance Imaging | 3 | 2023 | 83 | 0.380 |
Why?
| | Dementia, Vascular | 2 | 2008 | 16 | 0.380 |
Why?
| | Task Performance and Analysis | 1 | 2011 | 159 | 0.360 |
Why?
| | Cohort Studies | 9 | 2020 | 4903 | 0.330 |
Why?
| | Mental Status Schedule | 4 | 2016 | 33 | 0.310 |
Why?
| | Exosomes | 2 | 2020 | 91 | 0.300 |
Why?
| | Verbal Learning | 4 | 2019 | 63 | 0.300 |
Why?
| | Body Mass Index | 1 | 2013 | 1961 | 0.270 |
Why?
| | Frontal Lobe | 2 | 2019 | 140 | 0.260 |
Why?
| | Pilot Projects | 2 | 2021 | 1372 | 0.250 |
Why?
| | Apolipoproteins E | 4 | 2021 | 80 | 0.250 |
Why?
| | Cognitive Aging | 2 | 2023 | 13 | 0.250 |
Why?
| | Predictive Value of Tests | 3 | 2017 | 1801 | 0.240 |
Why?
| | Cerebral Amyloid Angiopathy | 1 | 2024 | 9 | 0.230 |
Why?
| | Risk Factors | 5 | 2020 | 8637 | 0.220 |
Why?
| | Neurites | 1 | 2023 | 43 | 0.220 |
Why?
| | Neuroimaging | 2 | 2023 | 248 | 0.220 |
Why?
| | Cross-Sectional Studies | 6 | 2021 | 4406 | 0.210 |
Why?
| | Blood-Brain Barrier | 1 | 2023 | 106 | 0.210 |
Why?
| | Central Nervous System | 1 | 2023 | 238 | 0.190 |
Why?
| | Amnesia | 4 | 2014 | 43 | 0.190 |
Why?
| | Apolipoprotein E4 | 1 | 2021 | 32 | 0.190 |
Why?
| | Reaction Time | 2 | 2015 | 374 | 0.180 |
Why?
| | Ultracentrifugation | 1 | 2020 | 48 | 0.180 |
Why?
| | Longevity | 1 | 2021 | 137 | 0.180 |
Why?
| | Proteins | 3 | 2016 | 912 | 0.180 |
Why?
| | Sleep, REM | 1 | 2020 | 50 | 0.180 |
Why?
| | Attention | 2 | 2016 | 392 | 0.170 |
Why?
| | Medication Therapy Management | 1 | 2021 | 67 | 0.170 |
Why?
| | Lewy Body Disease | 1 | 2020 | 16 | 0.170 |
Why?
| | Electroencephalography | 1 | 2021 | 362 | 0.170 |
Why?
| | Hearing Loss | 1 | 2023 | 184 | 0.170 |
Why?
| | Speech Disorders | 1 | 2019 | 30 | 0.170 |
Why?
| | Advance Care Planning | 1 | 2022 | 197 | 0.160 |
Why?
| | Myelin Sheath | 1 | 2021 | 144 | 0.160 |
Why?
| | Hippocampus | 2 | 2021 | 696 | 0.160 |
Why?
| | Leukoaraiosis | 2 | 2009 | 2 | 0.160 |
Why?
| | Gray Matter | 1 | 2019 | 67 | 0.160 |
Why?
| | Severity of Illness Index | 9 | 2016 | 2542 | 0.160 |
Why?
| | Educational Status | 1 | 2021 | 409 | 0.160 |
Why?
| | Chemokine CCL3 | 1 | 2018 | 15 | 0.160 |
Why?
| | Chemokine CCL4 | 1 | 2018 | 21 | 0.160 |
Why?
| | Myocardial Contraction | 1 | 2020 | 312 | 0.160 |
Why?
| | Psychiatric Status Rating Scales | 3 | 2017 | 483 | 0.150 |
Why?
| | Research | 1 | 2021 | 395 | 0.150 |
Why?
| | Neurogranin | 1 | 2017 | 2 | 0.150 |
Why?
| | Cytokines | 2 | 2018 | 1843 | 0.150 |
Why?
| | Mental Recall | 3 | 2017 | 170 | 0.150 |
Why?
| | Functional Laterality | 2 | 2019 | 197 | 0.140 |
Why?
| | Primary Progressive Nonfluent Aphasia | 2 | 2013 | 2 | 0.140 |
Why?
| | Time Factors | 3 | 2014 | 6125 | 0.140 |
Why?
| | Reproducibility of Results | 4 | 2018 | 2769 | 0.140 |
Why?
| | Autoantibodies | 2 | 2014 | 1354 | 0.140 |
Why?
| | Nanoparticles | 1 | 2020 | 313 | 0.140 |
Why?
| | Regression Analysis | 3 | 2020 | 947 | 0.140 |
Why?
| | Parkinson Disease | 2 | 2012 | 323 | 0.140 |
Why?
| | Neuropsychiatry | 1 | 2016 | 15 | 0.140 |
Why?
| | Heart Rate | 1 | 2020 | 705 | 0.130 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2018 | 1134 | 0.130 |
Why?
| | Sleep | 1 | 2021 | 632 | 0.130 |
Why?
| | Hypolipidemic Agents | 1 | 2017 | 87 | 0.130 |
Why?
| | Random Allocation | 1 | 2017 | 335 | 0.130 |
Why?
| | Chemokine CCL11 | 1 | 2015 | 22 | 0.130 |
Why?
| | Models, Anatomic | 1 | 2016 | 87 | 0.130 |
Why?
| | Amyloid | 1 | 2016 | 80 | 0.120 |
Why?
| | Communication | 1 | 2021 | 747 | 0.120 |
Why?
| | Factor Analysis, Statistical | 1 | 2016 | 257 | 0.120 |
Why?
| | Surveys and Questionnaires | 3 | 2022 | 4634 | 0.120 |
Why?
| | Triglycerides | 1 | 2017 | 470 | 0.120 |
Why?
| | Plaque, Amyloid | 1 | 2014 | 15 | 0.120 |
Why?
| | Prodromal Symptoms | 1 | 2014 | 11 | 0.120 |
Why?
| | Proteomics | 1 | 2020 | 844 | 0.120 |
Why?
| | Residence Characteristics | 1 | 2017 | 275 | 0.120 |
Why?
| | Carotid Intima-Media Thickness | 1 | 2014 | 65 | 0.120 |
Why?
| | Carotid Artery Diseases | 1 | 2014 | 57 | 0.120 |
Why?
| | Retina | 1 | 2016 | 263 | 0.120 |
Why?
| | Bradycardia | 1 | 2014 | 48 | 0.120 |
Why?
| | Aphasia, Broca | 1 | 2013 | 3 | 0.110 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 82 | 0.110 |
Why?
| | Frontotemporal Lobar Degeneration | 1 | 2013 | 8 | 0.110 |
Why?
| | Creutzfeldt-Jakob Syndrome | 1 | 2013 | 14 | 0.110 |
Why?
| | Aphasia, Primary Progressive | 1 | 2013 | 1 | 0.110 |
Why?
| | Prions | 1 | 2013 | 33 | 0.110 |
Why?
| | Language Development Disorders | 1 | 2013 | 38 | 0.110 |
Why?
| | Pacemaker, Artificial | 1 | 2014 | 107 | 0.110 |
Why?
| | Brain Diseases | 1 | 2014 | 125 | 0.110 |
Why?
| | Disease Progression | 2 | 2017 | 2392 | 0.110 |
Why?
| | Point Mutation | 1 | 2013 | 217 | 0.110 |
Why?
| | Hypercholesterolemia | 1 | 2013 | 90 | 0.110 |
Why?
| | Colorado | 1 | 2022 | 4089 | 0.100 |
Why?
| | Animals | 3 | 2023 | 31837 | 0.100 |
Why?
| | Down Syndrome | 1 | 2017 | 338 | 0.100 |
Why?
| | Adult | 6 | 2023 | 30604 | 0.100 |
Why?
| | Immunologic Factors | 1 | 2014 | 221 | 0.100 |
Why?
| | Linear Models | 1 | 2014 | 770 | 0.100 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2016 | 686 | 0.100 |
Why?
| | Macrophages | 1 | 2018 | 1266 | 0.100 |
Why?
| | Apraxias | 3 | 2019 | 7 | 0.090 |
Why?
| | Glucose | 1 | 2016 | 897 | 0.090 |
Why?
| | Comprehension | 2 | 2012 | 154 | 0.090 |
Why?
| | Statistics as Topic | 1 | 2011 | 294 | 0.090 |
Why?
| | Stress, Psychological | 1 | 2018 | 945 | 0.090 |
Why?
| | Longitudinal Studies | 4 | 2020 | 2382 | 0.090 |
Why?
| | Hypertension | 2 | 2020 | 1059 | 0.090 |
Why?
| | Psychomotor Disorders | 1 | 2010 | 17 | 0.090 |
Why?
| | Neurons | 1 | 2018 | 1282 | 0.090 |
Why?
| | Delivery of Health Care | 1 | 2017 | 834 | 0.090 |
Why?
| | Learning | 1 | 2013 | 352 | 0.090 |
Why?
| | Disability Evaluation | 2 | 2009 | 271 | 0.090 |
Why?
| | Age Factors | 1 | 2017 | 2891 | 0.080 |
Why?
| | Serial Learning | 1 | 2009 | 8 | 0.080 |
Why?
| | Genetic Predisposition to Disease | 1 | 2018 | 2102 | 0.080 |
Why?
| | Retrospective Studies | 6 | 2024 | 12543 | 0.080 |
Why?
| | Prospective Studies | 3 | 2014 | 6218 | 0.080 |
Why?
| | Language | 2 | 2008 | 258 | 0.080 |
Why?
| | Motor Skills | 1 | 2009 | 81 | 0.080 |
Why?
| | Young Adult | 2 | 2021 | 10476 | 0.080 |
Why?
| | Mental Disorders | 1 | 2016 | 891 | 0.080 |
Why?
| | Choice Behavior | 1 | 2010 | 155 | 0.080 |
Why?
| | Amyloid beta-Peptides | 2 | 2023 | 189 | 0.080 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2008 | 41 | 0.080 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2015 | 1893 | 0.080 |
Why?
| | Goals | 1 | 2009 | 151 | 0.080 |
Why?
| | Semantics | 1 | 2008 | 87 | 0.070 |
Why?
| | Insulin Resistance | 1 | 2015 | 1072 | 0.070 |
Why?
| | Models, Neurological | 1 | 2009 | 212 | 0.070 |
Why?
| | Cues | 1 | 2009 | 301 | 0.070 |
Why?
| | Peptide Fragments | 2 | 2023 | 668 | 0.070 |
Why?
| | Dopamine | 1 | 2009 | 235 | 0.070 |
Why?
| | Smoking | 1 | 2013 | 1391 | 0.070 |
Why?
| | Health Status | 1 | 2011 | 721 | 0.070 |
Why?
| | Sexual Dysfunction, Physiological | 1 | 2006 | 60 | 0.060 |
Why?
| | Psychotic Disorders | 1 | 2006 | 118 | 0.060 |
Why?
| | Adolescent | 2 | 2021 | 17826 | 0.060 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2017 | 797 | 0.060 |
Why?
| | Antipsychotic Agents | 1 | 2006 | 184 | 0.060 |
Why?
| | Analysis of Variance | 3 | 2012 | 1227 | 0.060 |
Why?
| | Amyloidogenic Proteins | 1 | 2023 | 9 | 0.060 |
Why?
| | Cerebral Hemorrhage | 1 | 2024 | 96 | 0.050 |
Why?
| | Child | 1 | 2021 | 18362 | 0.050 |
Why?
| | Schizophrenia | 1 | 2006 | 415 | 0.050 |
Why?
| | Intracellular Signaling Peptides and Proteins | 2 | 2014 | 386 | 0.050 |
Why?
| | Vision Disorders | 1 | 2023 | 130 | 0.050 |
Why?
| | Chemical Precipitation | 1 | 2020 | 38 | 0.050 |
Why?
| | Cardiac Electrophysiology | 1 | 2020 | 12 | 0.040 |
Why?
| | Diffusion | 1 | 2020 | 118 | 0.040 |
Why?
| | Regional Blood Flow | 1 | 2021 | 424 | 0.040 |
Why?
| | Cerebrovascular Circulation | 1 | 2021 | 220 | 0.040 |
Why?
| | Facial Expression | 1 | 2019 | 60 | 0.040 |
Why?
| | Language Tests | 2 | 2009 | 31 | 0.040 |
Why?
| | Problem Solving | 2 | 2009 | 141 | 0.040 |
Why?
| | Immunoassay | 1 | 2018 | 95 | 0.040 |
Why?
| | Nerve Degeneration | 1 | 2016 | 40 | 0.030 |
Why?
| | C9orf72 Protein | 1 | 2016 | 9 | 0.030 |
Why?
| | Independent Living | 1 | 2017 | 84 | 0.030 |
Why?
| | Interleukin-10 | 1 | 2018 | 296 | 0.030 |
Why?
| | Carbolines | 1 | 2016 | 27 | 0.030 |
Why?
| | Benzothiazoles | 1 | 2016 | 33 | 0.030 |
Why?
| | Interleukin-1beta | 1 | 2018 | 370 | 0.030 |
Why?
| | Aniline Compounds | 1 | 2016 | 71 | 0.030 |
Why?
| | Tomography, Optical Coherence | 1 | 2016 | 130 | 0.030 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 2015 | 56 | 0.030 |
Why?
| | Thiazoles | 1 | 2016 | 110 | 0.030 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2016 | 121 | 0.030 |
Why?
| | Judgment | 1 | 2015 | 55 | 0.030 |
Why?
| | Lipoproteins, LDL | 1 | 2015 | 128 | 0.030 |
Why?
| | Radionuclide Imaging | 1 | 2014 | 115 | 0.030 |
Why?
| | Photic Stimulation | 1 | 2015 | 203 | 0.030 |
Why?
| | Antigens, CD20 | 1 | 2014 | 28 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2016 | 265 | 0.030 |
Why?
| | Hyponatremia | 1 | 2014 | 37 | 0.030 |
Why?
| | Visual Perception | 1 | 2015 | 139 | 0.030 |
Why?
| | Fasting | 1 | 2015 | 242 | 0.030 |
Why?
| | Imaging, Three-Dimensional | 1 | 2017 | 517 | 0.030 |
Why?
| | Age of Onset | 1 | 2015 | 448 | 0.030 |
Why?
| | Genetic Testing | 1 | 2016 | 379 | 0.030 |
Why?
| | Caregivers | 2 | 2012 | 712 | 0.030 |
Why?
| | Rituximab | 1 | 2014 | 151 | 0.030 |
Why?
| | Fatal Outcome | 1 | 2013 | 285 | 0.030 |
Why?
| | Pedigree | 1 | 2013 | 467 | 0.030 |
Why?
| | Sickness Impact Profile | 1 | 2012 | 50 | 0.030 |
Why?
| | Seizures | 1 | 2014 | 340 | 0.020 |
Why?
| | Sex Characteristics | 1 | 2016 | 635 | 0.020 |
Why?
| | Genotype | 1 | 2015 | 1775 | 0.020 |
Why?
| | Cluster Analysis | 1 | 2011 | 460 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2015 | 1197 | 0.020 |
Why?
| | Blood Pressure | 1 | 2015 | 1537 | 0.020 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 1 | 2010 | 231 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2016 | 3008 | 0.020 |
Why?
| | Comorbidity | 1 | 2013 | 1458 | 0.020 |
Why?
| | Cerebral Ventricles | 1 | 2008 | 47 | 0.020 |
Why?
| | Differential Threshold | 1 | 2008 | 5 | 0.020 |
Why?
| | Geriatric Assessment | 1 | 2009 | 176 | 0.020 |
Why?
| | Intelligence Tests | 1 | 2007 | 59 | 0.020 |
Why?
| | Wechsler Scales | 1 | 2007 | 52 | 0.020 |
Why?
| | Speech Perception | 1 | 2008 | 79 | 0.020 |
Why?
| | Reading | 1 | 2008 | 149 | 0.020 |
Why?
| | DNA-Binding Proteins | 1 | 2013 | 1317 | 0.020 |
Why?
| | Benchmarking | 1 | 2008 | 161 | 0.020 |
Why?
| | Quetiapine Fumarate | 1 | 2006 | 22 | 0.020 |
Why?
| | Blood Glucose | 1 | 2015 | 1821 | 0.020 |
Why?
| | Dibenzothiazepines | 1 | 2006 | 17 | 0.020 |
Why?
| | Risperidone | 1 | 2006 | 26 | 0.020 |
Why?
| | Mutation | 1 | 2016 | 3353 | 0.020 |
Why?
| | Data Interpretation, Statistical | 1 | 2007 | 323 | 0.020 |
Why?
| | Benzodiazepines | 1 | 2006 | 116 | 0.020 |
Why?
| | Psychometrics | 1 | 2008 | 607 | 0.020 |
Why?
| | Motor Activity | 1 | 2009 | 641 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 2006 | 718 | 0.010 |
Why?
| | United States | 1 | 2020 | 12209 | 0.010 |
Why?
| | Outpatients | 1 | 2006 | 328 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2006 | 1856 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2014 | 9105 | 0.010 |
Why?
| | Depression | 1 | 2007 | 1133 | 0.010 |
Why?
|
|
Bettcher's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|